The therapeutic potential of 5-HT1A receptors: a patent review

Introduction: The 5-HT1A receptors are implicated in mood disorders (anxiety, depression), in cognition, and in modulation of pain. Nearly 30 years of research in this field, there is still interest in developing new chemical entities capable of 5-HT1A receptor activation or blockade. Areas covered: This review article will highlight and review the research advances published in the patent literature between January 2007 and December 2011, giving emphasis to the medicinal chemist's standpoint. Literature search methodology included search in Scifinder and PubMed Databases and browsing clinicaltrials.gov website. Expert opinion: Almost no new therapeutic applications have been proposed for molecules targeting the 5-HT1A receptor, during the years covered by the present review. The discovery that stimulation of 5-HT1A receptor can promote neurogenesis will likely renew the interest for selective 5-HT1A receptor agonists as therapeutics to replace neural populations damaged by disease or injury.

[1]  M. De Vivo,et al.  Characterization of the 5-hydroxytryptamine1a receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in guinea pig and rat hippocampal membranes. , 1986, The Journal of pharmacology and experimental therapeutics.

[2]  G. Aghajanian,et al.  Electrophysiological responses of serotoninergic dorsal raphe neurons to 5‐HT1A and 5‐HT1B agonists , 1987, Synapse.

[3]  C. de Montigny,et al.  Modification of 5‐HT neuron properties by sustained administration of the 5‐HT1A agonist gepirone: Electrophysiological studies in the rat brain , 1987, Synapse.

[4]  G. Aghajanian,et al.  Responses of hippocampal pyramidal cells to putative serotonin 5-HT1A and 5-HT1B agonists: A comparative study with dorsal raphe neurons , 1988, Neuropharmacology.

[5]  D. Middlemiss,et al.  Graphics computer-aided receptor mapping as a predictive tool for drug design: development of potent, selective, and stereospecific ligands for the 5-HT1A receptor. , 1988, Journal of medicinal chemistry.

[6]  J. Bockaert,et al.  Pharmacology of 5-hydroxytryptamine-1A receptors which inhibit cAMP production in hippocampal and cortical neurons in primary culture. , 1988, Molecular pharmacology.

[7]  M. Jann,et al.  Buspirone: An Update on a Unique Anxiolytic Agent , 1988, Pharmacotherapy.

[8]  S. Haj-Dahmane,et al.  Alterations of central serotoninergic and dopaminergic neurotransmission in rats chronically treated with ipsapirone: biochemical and electrophysiological studies. , 1990, The Journal of pharmacology and experimental therapeutics.

[9]  A. Akaike,et al.  Inhibition of hippocampal CA1 neurons by 5-hydroxytryptamine, derived from the dorsal raphe nucleus and the 5-hydroxytryptamine1A agonist SM-3997 , 1990, Neuropharmacology.

[10]  L. Acsády,et al.  Serotonergic control of the hippocampus via local inhibitory interneurons. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[11]  R. Fuller Role of serotonin in therapy of depression and related disorders. , 1991, The Journal of clinical psychiatry.

[12]  S. Watson,et al.  Comparative anatomical distribution of 5-HT1A receptor mRNA and 5-HT1A binding in rat brain — a combined in situ hybridisation/in vitro receptor autoradiographic study , 1991, Brain Research.

[13]  P. Hooff,et al.  Actions of 5‐hydroxytryptamine and 5‐HT1A receptor ligands on rat dorso‐lateral septal neurones in vitro , 1992, British journal of pharmacology.

[14]  T. Freund,et al.  GABAergic Interneurons are the Major Postsynaptic Targets of Median Raphe Afferents in the Rat Dentate Gyrus , 1992, The European journal of neuroscience.

[15]  M. Sketch,et al.  Effect of buspirone on withdrawal symptoms associated with smoking cessation. , 1992, Archives of internal medicine.

[16]  T. Bliss,et al.  A synaptic model of memory: long-term potentiation in the hippocampus , 1993, Nature.

[17]  J. Raymond,et al.  Cell-specific physical and functional coupling of human 5-HT1A receptors to inhibitory G protein alpha-subunits and lack of coupling to Gs alpha. , 1993, Biochemistry.

[18]  Iain P. Chessell,et al.  Neurotransmission—the link integrating Alzheimer research? , 1994, Trends in Neurosciences.

[19]  J. Cassel,et al.  Serotonergic modulation of cholinergic function in the central nervous system: Cognitive implications , 1995, Neuroscience.

[20]  Mustapha Riad,et al.  Immunocytochemical localization of serotonin1A receptors in the rat central nervous system , 1996, The Journal of comparative neurology.

[21]  D. Bakish,et al.  Serotonin in the Central Nervous System and Periphery. , 1997 .

[22]  M. Abate,et al.  Buspirone Use for Smoking Cessation , 1998, The Annals of pharmacotherapy.

[23]  T. Kojima,et al.  Anxiolytic 5-hydroxytryptamine1A agonists suppress firing activity of dorsal hippocampus CA1 pyramidal neurons through a postsynaptic mechanism: single-unit study in unanesthetized, unrestrained rats. , 1999, The Journal of pharmacology and experimental therapeutics.

[24]  J. Raymond,et al.  The recombinant 5‐HT1A receptor: G protein coupling and signalling pathways , 1999, British journal of pharmacology.

[25]  R. Ridley,et al.  The 5-HT1A antagonist, WAY 100 635, alleviates cognitive impairments induced by dizocilpine (MK-801) in monkeys , 2000, Neuropharmacology.

[26]  L. Levine,et al.  The 5-HT1A Receptor: an unkept promise? , 2000 .

[27]  L. Descarries,et al.  Somatodendritic localization of 5‐HT1A and preterminal axonal localization of 5‐HT1B serotonin receptors in adult rat brain , 2000, The Journal of comparative neurology.

[28]  trans-4-[4-(Methoxyphenyl)cyclohexyl]-1-arylpiperazines: a new class of potent and selective 5-HT(1A) receptor ligands as conformationally constrained analogues of 4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]-1-arylpiperazines. , 2001, Journal of medicinal chemistry.

[29]  Daniel Hoyer,et al.  Molecular, pharmacological and functional diversity of 5-HT receptors , 2002, Pharmacology Biochemistry and Behavior.

[30]  M. López-Rodríguez,et al.  Arylpiperazine derivatives acting at 5-HT(1A) receptors. , 2002, Current medicinal chemistry.

[31]  S. L. Nicholson,et al.  5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy. , 2002, European journal of neurology.

[32]  Judith S. Rose,et al.  Effects of buspirone in withdrawal from opiates. , 2003, The American journal on addictions.

[33]  P. Blier,et al.  Is there a role for 5-HT1A agonists in the treatment of depression? , 2003, Biological Psychiatry.

[34]  Yasuhiro Kaneda,et al.  Serotonin receptors : their key role in drugs to treat schizophrenia , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[35]  R. Galani,et al.  Intraseptal injection of the 5-HT1A/5-HT7 agonist 8-OH-DPAT and working memory in rats , 2004, Psychopharmacology.

[36]  Xiaojie Shi,et al.  Studies toward the discovery of the next generation of antidepressants. 3. Dual 5-HT1A and serotonin transporter affinity within a class of N-aryloxyethylindolylalkylamines. , 2004, Journal of medicinal chemistry.

[37]  C. J. Maclean,et al.  The 5-HT1A antagonist, WAY 100635, ameliorates the cognitive impairment induced by fornix transection in the marmoset , 2005, Psychopharmacology.

[38]  I. Lucki,et al.  Antidepressant-like activity of 5-HT1A agonists measured with the forced swim test , 2005, Psychopharmacology.

[39]  J. Barrett,et al.  Lecozotan (SRA-333): A Selective Serotonin 1A Receptor Antagonist That Enhances the Stimulated Release of Glutamate and Acetylcholine in the Hippocampus and Possesses Cognitive-Enhancing Properties , 2005, Journal of Pharmacology and Experimental Therapeutics.

[40]  F. Colpaert 5-HT(1A) receptor activation: new molecular and neuroadaptive mechanisms of pain relief. , 2006, Current opinion in investigational drugs.

[41]  O. Stiedl,et al.  5-Hydroxytryptamine 1A Receptor Blockade Facilitates Aversive Learning in Mice: Interactions with Cholinergic and Glutamatergic Mechanisms , 2006, Journal of Pharmacology and Experimental Therapeutics.

[42]  J. Castaǹer,et al.  Sarizotan hydrochloride : Antidyskinetic drug 5-HT1A receptor agonist dopamine D2 receptor ligand , 2006 .

[43]  O. Rascol,et al.  Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double‐blind placebo‐controlled trial , 2007, Movement disorders : official journal of the Movement Disorder Society.

[44]  Ji Woong Kim Role of 5-HT1A Receptors in Learning and Memory , 2007 .

[45]  P. Svenningsson,et al.  The role of 5-HT1A receptors in learning and memory , 2008, Behavioural Brain Research.

[46]  Charles A. Marsden,et al.  A role for the 5-HT1A, 5-HT4 and 5-HT6 receptors in learning and memory , 2008 .

[47]  E. Lacivita,et al.  5-HT1A receptor, an old target for new therapeutic agents. , 2008, Current topics in medicinal chemistry.

[48]  G. Mengod,et al.  Distribution and neurochemical characterization of neurons expressing GIRK channels in the rat brain , 2008, The Journal of comparative neurology.

[49]  Rony Seger,et al.  The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions. , 2010, Methods in molecular biology.

[50]  O. Rascol,et al.  Double‐blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[51]  K. Fabel,et al.  Oppositional Effects of Serotonin Receptors 5-HT1a, 2, and 2c in the Regulation of Adult Hippocampal Neurogenesis , 2009, Front. Mol. Neurosci..

[52]  R. Depoortère,et al.  F15599, a highly selective post-synaptic 5-HT(1A) receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity. , 2010, The international journal of neuropsychopharmacology.

[53]  S. Shimizu,et al.  Role of cortical and striatal 5-HT1A receptors in alleviating antipsychotic-induced extrapyramidal disorders , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[54]  L. Goff,et al.  Region- and phase-dependent effects of 5-HT1A and 5-HT2C receptor activation on adult neurogenesis , 2010, European Neuropsychopharmacology.

[55]  Abigail M Polter,et al.  5-HT1A receptor-regulated signal transduction pathways in brain. , 2010, Cellular signalling.

[56]  O. Rascol,et al.  Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials , 2011, Movement disorders : official journal of the Movement Disorder Society.

[57]  N. Meanwell Synopsis of some recent tactical application of bioisosteres in drug design. , 2011, Journal of medicinal chemistry.

[58]  A. Newman-Tancredi,et al.  Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties , 2011, Psychopharmacology.

[59]  Thomas Ruhland,et al.  Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. , 2011, Journal of medicinal chemistry.

[60]  G. Ming,et al.  Modification of hippocampal circuitry by adult neurogenesis , 2012, Developmental neurobiology.

[61]  L. Citrome Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? , 2014, International journal of clinical practice.